None
Quote | Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA)
Last: | $18.34 |
---|---|
Change Percent: | 3.73% |
Open: | $18.21 |
Close: | $17.68 |
High: | $18.46 |
Low: | $17.74 |
Volume: | 42,033 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
News | Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA)
2024-04-23 13:59:07 ET Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice Preside...
2024-04-23 07:37:59 ET More on Kiniksa Pharmaceuticals Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals Historical earnings data for Kiniksa Pharmaceuticals Financial information for Kiniksa Pharmaceuticals Read the full article on Seeking Alp...
Message Board Posts | Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: KNSA 22% v1,2M c12.73 f68,5M H13.55 | znewcar1 | investorshangout | 11/01/2021 10:46:33 PM |
No bueno. I guess $HGEN's lenzilumab is | DonDonDonDon | investorshub | 04/01/2021 11:24:49 PM |
It was recently discovered that the protein GM-CSF | DonDonDonDon | investorshub | 03/22/2021 2:17:19 PM |
PT= $30-40 (by or around March 31st) | Femto99 | investorshub | 02/26/2021 11:28:28 PM |
PDUFA Mar21 | Femto99 | investorshub | 02/10/2021 6:44:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Kiniksa Pharmaceuticals Ltd. Company Name:
KNSA Stock Symbol:
NASDAQ Market:
– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjög...
Kiniksa Pharmaceuticals Ltd. (KNSA) is expected to report $-0.14 for Q1 2024 Agree Realty Corporation (ADC) is expected to report $1.01 for Q1 2024 1st Colonial Bancorp Inc (FCOB) is expected to report for Q1 2024 Equity Residential of Beneficial Interest (EQR) is expected to report $...
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio ...